Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)

NCT00761007 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

554

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome

Interventions

DRUG: Ibodutant
DRUG: Ibodutant
DRUG: Ibodutant
DRUG: Placebo

Sponsor

Menarini Group